dx8951

Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg mL).Exatecan has antitumor activity and may be used in cancer research.

MC-GGFG-DX8951 (MC-GGFG-Exatecan) is an antibody-coupled drug (ADC) drug-linker conjugate (DLC) consisting of DX8951, a potent DNA topoisomerase I inhibitor, the linker MC, and the cleavable peptide chain GGFG, and has antitumor potential.

DBCO-PEG4-GGFG-DX8951 is a click-reactive Drug-linker that contains a DBCO group and can undergo a strain-promoted acetylene-nitride cycloaddition reaction (SPAAC) with molecules containing an Azide group. DX8951 is a DNA topoisomerase I (topoisomerase I) inhibitor. DBCO-PEG4-GGFG-DX8951 can be used in the synthesis of antibody-drug conjugates (ADCs).

Py-MAA-Val-Cit-PAB-DX8951, a purine toxin, serves as an intermediate in the synthesis of antibody-drug conjugates [1].

MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a conjugate of the DNA topoisomerase I inhibitor DX-8951 and a cathepsin-cleavable antibody-drug conjugate (ADC) linker, designed for targeted cancer therapy applications.

Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) serves as a conjugate of an agent-linker for antibody-drug conjugates (ADC). This compound consists of the DNA topoisomerase I inhibitor DX-8951 and a cathepsin-cleavable ADC linker [1].

Val-Cit-PAB-Exatecan TFA (Val-Cit-PAB-DX8951 TFA) forms part of an antibody-drug conjugate (ADC). The compound consists of the DNA topoisomerase I inhibitor DX-8951 and a protease-degradable ADC linker.